Pacific Biosciences Grants Equity Incentive Award to New Employee
Pacific Biosciences (NASDAQ: PACB) announced on September 24, 2021, that its Compensation Committee granted stock options for 100,000 shares and restricted stock units (RSUs) for 50,000 shares to a new employee. These awards are part of the 2020 Inducement Equity Incentive Plan, introduced to attract new talent. The stock options have an exercise price of $27.99, equal to the stock's closing price on the grant date. The vesting schedule includes milestones at one year and monthly thereafter for options, while RSUs vest over four years.
- Granting 100,000 stock options and 50,000 RSUs may enhance employee retention and motivation.
- The use of the 2020 Inducement Plan indicates a strategic approach to attract key talent.
- None.
MENLO PARK, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of Pacific Biosciences common stock, and restricted stock units (“RSUs”) covering 50,000 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020 Inducement Plan”) effective on September 20, 2021.
The 2020 Inducement Plan is used exclusively to grant equity awards to individuals who were not previously an employee or non-employee director of Pacific Biosciences as an inducement material to such individual’s entering into employment with Pacific Biosciences in accordance with Nasdaq Marketplace Rule 5635(c)(4).
The options have an exercise price of
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.
Contacts Investors:
Todd Friedman 650.521.8450
ir@pacificbiosciences.com
Media:
Jen Carroll 858.449.8082
pr@pacificbiosciences.com
FAQ
What recent employee compensation changes did PACB announce?
What is the exercise price for the newly granted stock options by PACB?
What is the vesting schedule for the stock options granted by PACB?